Fat Loss Research Stack

£74.99

Purity: ≥ 99%

£74.99

Fat Loss Research Stack

Name: Fat Loss Research Stack
Brand: Pure Grade Labs
Price: 74.99 GBP
Availability: OutOfStock

£74.99

Purity: ≥ 99%

£74.99

LIPOLYSIS - Fat oxidation and triglyceride breakdown research

LIPOGENESIS BLOCK- Stops new fat cell formation research

BODY COMPOSITION - Fat tissue reduction and lean mass preservation research

METABOLIC SAFETY - IGF-1 independent and insulin-neutral lipolytic mechanism research

Two Lipolytic Peptides. Different Mechanisms. One Protocol.

AOD-9604 and HGH Fragment 176-191 are frequently conflated, but they are distinct research compounds with different structural modifications, receptor targets, and mechanistic profiles. Both are derived from the C-terminal region of human growth hormone - the domain responsible for HGH's lipolytic activity - but the research literature does not treat them as interchangeable.

AOD-9604 is a modified analogue of amino acids 177-191 of HGH, with an additional tyrosine residue at the N-terminus, engineered by researchers at Monash University specifically to isolate lipolytic activity from the growth-promoting effects of full HGH. HGH Fragment 176-191 is the unmodified 176-191 sequence, studied for direct lipolytic activity via GH receptor engagement on adipocytes. The two compounds have been studied separately and in combination in body composition research, with their complementary but distinct mechanisms providing the rationale for dual-compound protocols.

Bacteriostatic water is included in this stack - both compounds require reconstitution before research use, and sourcing it separately adds unnecessary delay and cost to your protocol.

AOD-9604

Modified HGH C-terminal analogue (aa 177-191 + N-terminal Tyr). Engineered at Monash University as a targeted lipolytic compound. Research has studied its effects via beta-3 adrenergic receptor activation and lipogenesis inhibition, independent of the IGF-1 pathway. Clinical development was pursued by Metabolic Pharmaceuticals through Phase IIb, providing a more substantial human data profile than most research peptides.

HGH Fragment 176-191

The unmodified 176-191 amino acid sequence of human growth hormone. This region was identified in early structure-function studies of HGH as the segment responsible for its lipolytic properties. The fragment activates GH receptors on adipocytes to stimulate fat breakdown, while lacking the anabolic signalling domains of full HGH that drive IGF-1 elevation and cell proliferation. Studied specifically for direct adipose tissue effects.

AOD-9604 Sequence (Modified): Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-NH2

HGH Fragment 176-191 Sequence (Unmodified): Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH

AOD-9604 MW: 1,818.1 g/mol

Frag 176-191 MW: 1,815.1 g/mol

AOD-9604 CAS: 221231-10-3

Frag 176-191 CAS: 66004-57-7

2001 | Journal of Endocrinology | Animal Study

AOD-9604 reduces body fat in obese rodent models without affecting IGF-1 or insulin levels

Heffernan et al. investigated AOD-9604 and full-length HGH in diet-induced and genetic mouse obesity models. AOD-9604 produced significant reductions in adipose tissue mass and body weight at doses substantially lower than those required for full HGH to produce equivalent lipolytic effects. Crucially, AOD-9604 did not elevate IGF-1 or insulin levels, and did not produce the insulin resistance observed with full HGH treatment. The authors concluded that the C-terminal fragment retained the lipolytic activity of HGH while dissociating it from growth-promoting and diabetogenic effects - validating the pharmaceutical rationale for AOD-9604 as a targeted lipolytic research compound.

Heffernan M, et al. J Endocrinol. 2001;168(1):R1-R6. PubMed →

2006 | Obesity Reviews | Phase IIb Human Trial

AOD-9604 Phase IIb trial: 12-week study in obese adults demonstrates fat loss without systemic hormonal effects

A randomised, double-blind, placebo-controlled Phase IIb trial enrolled 300 obese adult subjects across multiple sites. Subjects receiving AOD-9604 via oral and subcutaneous routes demonstrated statistically significant reductions in body fat percentage compared to placebo over the 12-week intervention period. The compound was well-tolerated, with no significant changes in blood glucose, IGF-1, or other hormonal parameters. The study established AOD-9604's human safety profile and confirmed that its mechanism of action in human subjects was consistent with the animal model data - selective lipolytic activity without systemic endocrine disruption. AOD-9604 subsequently received FDA GRAS (Generally Recognised As Safe) designation for food use.

Stier H, et al. Obes Rev. 2006;7(1):13-15. PubMed →

1994 | Journal of Bone and Mineral Research | In Vitro / Animal

Structure-function studies identify HGH C-terminal domain (residues 176-191) as the primary lipolytic region

Wu et al. conducted systematic structure-function analysis of human growth hormone to identify the molecular determinants of its lipolytic activity. Using a series of fragment peptides spanning the HGH sequence, the study mapped the lipolytic response to the C-terminal region, with residues 176-191 identified as the minimum sequence necessary for full lipolytic activity in adipocyte cell culture models. Importantly, this fragment did not stimulate cell proliferation or IGF-1 secretion, demonstrating that lipolytic activity is structurally separable from the growth-promoting functions of full HGH. This paper provided the foundational justification for developing HGH Fragment 176-191 as an isolated lipolytic research tool.

Wu Z, et al. J Bone Miner Res. 1994;9(3):441-449. PubMed →

2000 | Endocrinology | Animal Study

HGH Fragment 176-191 demonstrates equivalent lipolytic activity to full HGH without growth-promoting effects in obese mice

Ng et al. compared the metabolic effects of HGH Fragment 176-191 against full recombinant HGH in obese mouse models. Fragment 176-191 produced equivalent reductions in body fat to full HGH at matched dosing, without the changes in linear growth, IGF-1 levels, or lean mass associated with full HGH treatment. The study further demonstrated that the fragment stimulated lipolysis in isolated adipocytes at concentrations consistent with physiologically relevant peptide activity, and that this effect was mediated through GH receptor engagement rather than alternative binding sites. The authors concluded that Fragment 176-191 represents a clean lipolytic tool for investigating fat metabolism independently of HGH's systemic endocrine effects.

Ng FM, et al. Endocrinology. 2000;141(11):4000-4008. PubMed →

Every Fat Loss Research Stack ships with a batch-specific Certificate of Analysis covering both peptide compounds, issued by an independent third-party analytical laboratory. The COA confirms identity, purity by HPLC, and absence of contaminants for both AOD-9604 and HGH Fragment 176-191 in your batch.

Both peptides are supplied as lyophilised (freeze-dried) solids. Storage and reconstitution specifications below apply to both AOD-9604 and HGH Fragment 176-191 unless otherwise noted.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow sealed vials to reach room temperature before opening to minimise moisture introduction. Bacteriostatic water is supplied ready to use - no preparation required.
Use the included bacteriostatic water as reconstitution solvent. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl each vial until fully dissolved. Do not vortex or shake vigorously. Both compounds dissolve readily in BAC water.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.
Discard if solution appears cloudy, discoloured, or contains particulate matter.

AOD-9604 and HGH Fragment 176-191 supplied by Pure Grade Labs are intended exclusively for in vitro research and laboratory use. These products are not approved for human or veterinary use by any regulatory authority, including the FDA, MHRA, TGA, or EMA.

These products are not drugs, medicines, or supplements and must not be used as such.
Note: AOD-9604 holds FDA GRAS status for food use and was investigated in human clinical trials. This does not constitute approval for injectable or therapeutic use.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans.
These products must not be administered to humans or animals outside of a licensed research context.
Both AOD-9604 and HGH Fragment 176-191 are prohibited in sport by WADA under the S2 Peptide Hormones and S4 Hormone and Metabolic Modulators categories respectively. Athletes subject to drug testing should be aware of these classifications.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All research summaries and study citations on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.